SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; “Modalis”), a ...

Solve FSHD, established by Canadian entrepreneur Chip Wilson, aims to expedite research to find a cure for FSHD. The Wilson family has pledged $100m to support projects aligned with this mission. In ...

Armatus Bio Inc.’s development of ARM-201, an AAV-delivered microRNA therapy for facioscapulohumeral muscular dystrophy (FSHD), has been boosted by a $3 million investment by Solve FSHD.

SOLVE FSHD, a venture philanthropy organization committed to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today announced a $3 m ...

在研究 fshd 发病机制时，存在现有模型无法解释不完全外显等问题。研究人员针对 4q35 区域基因转录和染色质特征展开研究，发现其存在不同调控模式，转录本受 d4z4 重复长度影响。这为理解 fshd 发病机制提供新视角。

SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with ...

Lhermitte’s sign is sometimes described as an electrical sensation in your neck. Discover how it relates to multiple sclerosis, other causes, and more.

This molecular mechanism makes FSHD distinct from other muscular dystrophies. Unlike Duchenne muscular dystrophy, which results from mutations in the DMD gene, or myotonic dystrophy caused by repeat ...

Finding a treatment for FSHD. Like other forms of muscular dystrophy, FSHD is marked by muscle weakness that worsens over time. FSHD usually most severely affects the muscles around the face, shoulder ...